BOULDER, Colo., Oct. 2, 2018 /PRNewswire/ — Prima-Temp, a company pioneering chronobiological healthcare for women, is pleased to announce the recent acquisition of Kindara Inc., a Colorado-based digital health company with a successful fertility platform. The acquisition expands and reinforces Prima-Temp’s commercial presence in the fertility marketplace and provides a proven platform and additional commercial resources for the launch of the Priya Personal Fertility Sensor, anticipated internationally in the first half of 2019 and in the United States in the second half of 2019.
Kindara offers one of the most popular fertility apps on the market with over 1.5 million downloads. Kindara’s fertility app pairs with Wink by Kindara, a Bluetooth-connected thermometer that helps seamlessly track fertility data with greater ease and accuracy. The app, in addition to being a comprehensive fertility charting tool, is also a robust social platform on which over 800,000 women interested in the fertility awareness method can create groups and share information with each other or practitioners.
“Kindara shares our mission to offer women the tools, knowledge and support to take control of their reproductive health and meet their fertility goals. The acquisition of Kindara provides Prima-Temp a strategic opportunity to rapidly expand our presence in the market with experienced team members, a proven commercialization infrastructure and a dedicated community of women focused on their fertility – all of which will pave the way for the commercialization of the Priya Personal Fertility Sensor in 2019,” commented Alene A Campbell, Chief Executive Officer of Prima-Temp.
Priya harnesses the power of circadian rhythm and machine learning, empowering women to effortlessly and accurately manage their fertility in real-time. The Priya system includes a self-inserted vaginal ring and the Priya app. By continuously and passively monitoring core body temperature, Priya’s smart technology, powered by artificial intelligence (AI), identifies the subtle patterns that occur prior to ovulation. When a woman is most fertile, a notification is sent to the smart device.
“It is clear from user feedback received from the Kindara community and our primary market research, women are seeking an effortless solution without sacrificing accuracy. Kindara women in this profile will clearly benefit from the advancement found in our sophisticated AI, and Prima-Temp will likewise benefit from the wisdom of the Kindara community,” Ms. Campbell commented further.
Prima-Temp believes there is a significant unmet need and corresponding significant market opportunity for supporting women’s fertility. Approximately 4 million women are trying to conceive each year in the United States. The current U.S. market for fertility products is estimated to be $151 million annually and projected to grow to $216.8 million by 2020 with a compound annual growth rate (CAGR) of 7.5%. Over 1.9 million women are purchasing ovulation prediction kits and an estimated 5 million are downloading fertility apps to aide in the conception process.
Based on the science of circadian rhythms, the Priya Personal Fertility Sensor offers precise, continuous core body temperature measurement which is interpreted by a proprietary A.I. (artificial Intelligence) algorithm developed by Prima-Temp to identify when the different phases of a woman’s menstrual cycle occur and wirelessly communicate this information to a smart phone. Initially, Priya will be marketed to physicians and directly to the 4 million women trying to conceive each year in the United States as the most sophisticated, accurate and effortless method of predicting ovulation and improving the chance of conception. Future opportunities identified for the Priya Sensor include use by healthcare practitioners in the diagnosis and management of infertility, including ovulation disorders and luteal phase defect. Additional applications include use in natural cycle IVF and natural family planning.
Prima-Temp is pioneering chronobiological healthcare for women. The company combines chronobiology and advanced intelligence machine learning, utilizing circadian rhythm patterns to track and alert as to a variety of important health parameters. The emerging science of recurring biologic signals with time-dependent features is discovering predictive patterns from hormonal shifts, sleep disorders, metabolism and can potentially be used to improve cancer chemotherapy timing, and early identification of sepsis. Prima-Temp is harnessing the science of the circadian clock, which was recently awarded the Nobel prize for medicine, to address many of today’s women’s health issues.